Results 191 to 200 of about 101,286 (277)

Precision medicine in cutaneous melanoma—A comprehensive review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source

Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer. [PDF]

Int J Clin Oncol
Wang HT, Yu YL, Lo WJ, Lin MC, Chu CL, Chen CY, Wang ST, Chiu CF, Bai EJ, Bai LY.   +9 more
europepmc   +1 more source

Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]

, 2018
Bradley, Jeffrey D, et al,
core   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial. [PDF]

JAMA Oncol
Carlino MS, Gao B, Michael M, Marshall H, Gunjur A, Chan H, Zielinski R, So J, Harris SJ, Kee D, Collins IM, Lam WS, Lyle M, Underhill C, Brown MP, Harrup R, Wong SF, Grady J, Ballinger M, Tavancheh E, Thomas DM, Palmer J, Wilkie K, Cebon J, Klein O.   +24 more
europepmc   +1 more source

scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions

Journal of the European Academy of Dermatology and Venereology, EarlyView.
CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu, Agata Kurowski, Malini P. Naidu, Jonas Adalsteinsson, Shane A. Meehan, Natalia Alkon, Lauren R. Port, Sumanth Chennareddy, Emry R. Cohenour, Grace Christensen, Jonah Shulman, Nicholas Gulati, Constanze Jonak, Patrick M. Brunner   +13 more
wiley   +1 more source

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel, Sabrina Bänsch, Laura Adam, Nathan Fekade, Alessandra Rünger, Tim Zell, Daniel J. Smit, Julian Kött, Isabel Heidrich, Michael Weichenthal, Selma Ugurel, Ulrike Leiter, Peter Mohr, Alexandra Geusau, Stephan Grabbe, Markus V. Heppt, Ralf Gutzmer, Jochen Utikal, Jan‐Christoph Simon, Sebastian Haferkamp, Laura Susok, Bastian Schilling, Edgar Dippel, Imke von Wasielewski, Jessica C. Hassel, Carola Berking, Stefan W. Schneider, Christoffer Gebhardt   +27 more
wiley   +1 more source

Encephalitis and Immune-Related Complications in a Patient Treated With Nivolumab: A Case Report. [PDF]

Case Rep Med
Lyras G, Karydis P, Tetradi SD, Lechouriti AM, Potsios C, Taprantzi D, Michailides C, Velissaris D.   +7 more
europepmc   +1 more source

Endoscopic features of deficient mismatch repair/microsatellite instability‐high and BRAF‐mutated colorectal cancer

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Objective Recent advancements in genome analyses, including the BRAF gene and mismatch repair (MMR) gene/microsatellite instability (MSI), have revealed the biological diversity of colorectal cancer (CRC). BRAF‐mutated CRC has a poor prognosis; however, cases exhibiting deficient MMR (dMMR)/MSI‐high (MSI‐H) and BRAF gene mutations have ...
Rika Omote, Shizuma Omote, Ryohei Sumii, Joichiro Horii, Isao Fujita, Hideaki Miyaso, Tatsuya Toyokawa, Masaru Inagaki   +7 more
wiley   +1 more source

Re-defining standards of care in resectable head and neck squamous cell carcinoma-lessons from KEYNOTE-689 and NIVOPOSTOP. [PDF]

Oncologist
Mehra S, Yom SS, Burtness B.
europepmc   +1 more source